Indaptus Therapeutics (NASDAQ:INDP) Stock Price Down 1% – Here’s What Happened

Indaptus Therapeutics, Inc. (NASDAQ:INDP)’s stock price fell 1% on Friday . The company traded as low as $0.99 and last traded at $1.00. 15,486 shares changed hands during mid-day trading, a decline of 74% from the average session volume of 60,416 shares. The stock had previously closed at $1.01.

Wall Street Analyst Weigh In

A number of research firms have weighed in on INDP. HC Wainwright reiterated a “buy” rating and issued a $12.00 target price on shares of Indaptus Therapeutics in a research note on Wednesday, October 16th. Maxim Group dropped their price objective on Indaptus Therapeutics from $8.00 to $5.00 and set a “buy” rating on the stock in a research note on Wednesday, November 13th.

Indaptus Therapeutics Stock Performance

The company’s 50 day simple moving average is $1.18 and its 200-day simple moving average is $1.66. The firm has a market capitalization of $10.20 million, a PE ratio of -0.58 and a beta of 1.46.

Indaptus Therapeutics (NASDAQ:INDP) last announced its earnings results on Tuesday, November 12th. The company reported ($0.32) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.47) by $0.15. On average, equities research analysts forecast that Indaptus Therapeutics, Inc. will post -1.79 earnings per share for the current fiscal year.

Indaptus Therapeutics Company Profile

Indaptus Therapeutics, Inc, a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial.